Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | GSK3B | P49841 | 2/20 | 0.57 |
| ▸ | PIM1 | P11309 | 2/20 | 0.56 |
| ▸ | CDC25A | P30304 | 3/20 | 0.54 |
| ▸ | CDC25B | P30305 | 3/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.51 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.51 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.51 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649520 | 1.00 | NPC1 (0.67) | NPC1RAB9APOLBSMN1; SMN2TDP1 | |
| SCHEMBL648557 | 0.81 | NPC1 (0.61) | NPC1RAB9APOLBSMN1; SMN2TDP1 | |
| SCHEMBL648666 | 0.81 | NPC1 (0.61) | NPC1RAB9APOLBSMN1; SMN2TDP1 | |
| SCHEMBL650962 | 0.79 | NPC1 (0.62) | NPC1RAB9APOLBSMN1; SMN2TDP1 | |
| SCHEMBL649057 | 0.79 | NPC1 (0.62) | NPC1RAB9APOLBSMN1; SMN2TDP1 | |
| SCHEMBL4143757 | 0.78 | MEN1 (1.00) | NPC1RAB9APOLBSMN1; SMN2TDP1 | |
| SCHEMBL4143758 | 0.78 | MEN1 (1.00) | NPC1RAB9APOLBSMN1; SMN2TDP1 | |
| SCHEMBL649940 | 0.78 | NPC1 (0.61) | NPC1RAB9APOLBSMN1; SMN2TDP1 | |
| SCHEMBL649939 | 0.78 | NPC1 (0.61) | NPC1RAB9APOLBSMN1; SMN2TDP1 | |
| SCHEMBL650721 | 0.76 | NPC1 (0.61) | NPC1RAB9APOLBSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423204-A1 | THIAZOLIDINONE DERIVATIVE | SBI Biotech Co., Ltd. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-8119812-B2 | Thiazolidinone derivative | SBI BIOTECH CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-8119812-B2 | Thiazolidinone derivative | SBI BIOTECH CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-8119812-B2 | Thiazolidinone derivative | SBI BIOTECH CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | SBI BIOTECH CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | SBI BIOTECH CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | SBI BIOTECH CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
| WO-2010122979-A1 | THIAZOLIDINONE DERIVATIVE | ＳＢＩバイオテック株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | CDC7, CDK17, CDCA2 | NPC1 1074/4885RAB9A 3157/4885POLB 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.